no-img_author.png
Verschiedene
Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.
Re-irradiation and hyperthermia after surgery for recurrent breast cancer.
Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer-A Phase I-II Study.
Exploiting dendritic cells in the development of cancer vaccines.
Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.
Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.
Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer-A Phase I-II Study.
Exploiting dendritic cells in the development of cancer vaccines.
Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.
Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.
Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.
Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.
Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.
Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunothe
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells.
Current status of immunotherapy for the treatment of biliary tract cancer.
Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.
Vaccine strategies for glioblastoma: progress and future directions.
Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.
Hyperthermia induces cytoskeletal alterations and mitotic catastrophe in p53-deficient H1299 lung cancer cells.
Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients.
[Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.
Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication.
Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo.
Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy.
Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo.
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients.
Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells.
Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report.
Immunotherapy with tumor vaccines for the treatment of malignant gliomas.
Reirradiation and hyperthermia for radiation-associated sarcoma.
Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope
Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer.
Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.
Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus.
New perspectives in glioma immunotherapy.
Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells.
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study.
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.
[Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo].
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic a
Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer.
Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma
Radiotherapy combined with hyperthermia for primary malignant melanomas of the esophagus.
Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate.
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.
Immunotherapy of hepatocellular carcinoma.
Dendritic cells fused with allogeneic hepatocellular carcinoma cell line compared with fused autologous tumor cells as hepatocellular carcinoma vaccines.
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.
Advances in cellular therapy for the treatment of thyroid cancer.
Mechanisms of murine dendritic cell antitumor dysfunction in aging.
Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.
Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.
Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.
Immunotherapy of acute myeloid leukemia: current approaches.
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.
Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies.
In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens.
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.
Radiotherapy with 8-MHz radiofrequency-capacitive regional hyperthermia for stage III non-small-cell lung cancer: the radiofrequency-output power correlates with the intraesophageal temperature and cl
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection.
Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
The anti-tumor effect of human monocyte-derived dendritic cells loaded with HSV-TK/GCV induced dying cells.
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.
Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C).
In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.
Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia.
Dendritic cells and T lymphocyte interactions in patients with lymphoid malignancies.
CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.
Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia re
Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell
Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus.
Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.
Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus.
Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile.
Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells.
Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.
Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immuno
Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case.
Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies.
Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.
Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens.
Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70.
Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3.
Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection.
Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood.
Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma.
[The effect of stimulation of dendritic cell on HBV-epitopic cytotoxic T-lymphocyte].
Effects of dendritic cells transfected with full length wild-type p53 and modified by bile duct cancer lysates on immune response.
A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery.
Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma.
Clinical significance of immune cell infiltration within gallbladder cancer.
Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunothe
Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells.

Nikolausberger Weg 56

37073 Göttingen

Tel.: 0049 551 43121